<DOC>
	<DOCNO>NCT02818556</DOCNO>
	<brief_summary>This single-center , randomize , evaluator-blinded , split-face clinical study design . Fifty patient receive one treatment session consist Restylane® Silk ( right side face ) Belotero Balance® ( left side ) , vice versa ( 1:1 dose conversion ratio ) injection superficial , vertical perioral line . Injections perform baseline visit . To ensure subject investigator blinding , syrinx prepare label `` 1 '' `` 2 '' immediately subject attendance injection sub-investigator . The injection sit technique use side face . Then , patient follow-up post-treatment day 7 , 14 , 30 , 60 , 90 , 120 , 150 , 180 .</brief_summary>
	<brief_title>A Clinical Study Comparing Restylane® Silk Belotero Balance® Treatment Superficial , Vertical Perioral Lines</brief_title>
	<detailed_description />
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Patients exhibit moderate [ 2 ] severe [ 3 ] superficial , vertical perioral line 5point Merz® validate scale assessment superficial perioral line Females male good general health age 18 year old Must willing give sign HIPAA form , informed consent form photographic release form Patient planning undergo Restylane® Silk Belotero Balance® injection For female patient childbearing potential , must regular menstrual cycle prior study entry ( female consider childbearing potential unless postmenopausal , without uterus and/or ovary , bilateral tubal ligation ) willing use acceptable form birth control entire course study [ i.e. , acceptable method birth control oral contraceptive , contraceptive patches/rings/implants Norplanit® , DepoProvena® , doublebarrier method ( e.g . condom spermicide ) , abstinence vasectomy partner document second acceptable method birth control patient become sexually active ] . All systemic birth control measure must consistent use least 30 day prior study participation Negative urine pregnancy test result time study entry ( applicable ) Must willing comply study regimen complete entire course study . A patient uncontrolled systemic disease . A potential patient therapy systemic disease yet stabilize consider entry study A patient significant history current evidence medical , psychological disorder , investigator 's opinion , would preclude enrollment study . A patient know hypersensitivity component study medication A patient actively smoke plan smoke time duration study A patient active skin condition/disease might interfere diagnosis evaluation study parameter ( i.e. , atopic dermatitis , eczema , psoriasis , seborrheic dermatitis , herpes labialis ) A patient planning cosmetic procedure facial area study period , treatment perform investigator A patient use topical ( prescription counter ) medicate cream , lotion , gel , balm , powder , etc . treatment area study period A patient receive topical product contain alphahydroxy acid , salicylic acid , vitamins C D ( include derivative thereof ) perioral area within 7 day prior study period , study product A patient receive investigational drug and/or microdermabrasion ( light medium skin peel ) treatment perioral area within 30 day prior study period A patient use topical tretinoin product derivative perioral area within 12 week prior study period A patient receive chemical peel , systemic steroid , nonablative laser , light radio frequency treatment and/or dermabrasion ( deep skin peel ) ablative laser treatment perioral area must discontinue drug/treatment and/or procedure least 6 month prior enter study A patient previously treat botulinum toxin perioral area within past six month A patient previously treat dermal filler perioral area within past year A patient history allergic reaction dermal filler lidocaine A patient history permanent filler perioral area A female patient pregnant , nurse infant planning pregnancy study [ throughout course study , woman childbearing potential must use reliable form contraception ( i.e. , oral contraceptive , intrauterine device , abstinence , spermicide condom use combination ) ] Current participation participation within 30 day prior start study drug investigational research study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>